U.S. Markets close in 1 hr 48 mins

Mind Cure Health Inc. (MCURF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3475-0.0026 (-0.74%)
As of 1:31PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3501
Open0.3350
BidN/A x N/A
AskN/A x N/A
Day's Range0.3350 - 0.3589
52 Week Range0.2540 - 0.6310
Volume66,833
Avg. Volume294,279
Market Cap32.339M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
    CNW Group

    MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

    Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, announces the filing of provisional patent applications with the United States Patent and Trademark Office (USPTO) for innovative processes for synthesizing ibogaine.

  • MINDCURE Adopts Advance Notice Policy
    CNW Group

    MINDCURE Adopts Advance Notice Policy

    Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company with respect to nominations of directors to the Company's Board ("Advance Notice Policy").

  • Maxim Group Initiates Coverage of Mind Cure Health
    CNW Group

    Maxim Group Initiates Coverage of Mind Cure Health

    Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE.